Targets › EPHA2
5 programs from 5 companies in 6 trials: 5 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. (UniProt, P29317)
Open in Phaseline: the race on EPHA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BicycleTx | nuzefatide pevedotin (BT5528) EphA2-targeting antibody-drug conjugate | EPHA2 | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumor Historically Known for High EphA2 Expression | Dec 2026 |
| Chinese PLA General Hospital | TP53-EphA-2-CAR-DC TP53 mutant peptide-loaded, EphA2-targeting CAR dendritic cell vaccine | TP53, EPHA2 | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| M.D. Anderson Cancer Center | EphA2-targeting DOPC-encapsulated siRNA EphA2 siRNA (gene silencing) | EPHA2 | Phase 1 | Advanced Malignant Solid Neoplasm | Apr 2027 |
| Tianjin ConjuStar Biologics | SC-102 EphA2-targeting peptide conjugate with tubulin inhibitor | EPHA2 | Phase 1 | Advanced Solid Cancers | Jun 2027 |
| Mustafa Khasraw, MBChB, MD, FRCP, FRACP | P30-EPS Vaccine Peptide-based tumor-associated antigen vaccine targeting EphA2, CMV pp65, and Survivin lin | EPHA2, BIRC5 | Phase 1 | Glioma, Malignant | Feb 2028 |
Advanced Malignant Solid Neoplasm (1) Advanced Solid Cancers (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Advanced Solid Tumor Historically Known for High EphA2 Expression (1) Solid Tumor, Adult (1) Glioma, Malignant (1)
mixed (2), other (1), small molecule (1), antibody (1)
M.D. Anderson Cancer Center (1) Tianjin ConjuStar Biologics (1) BicycleTx (1) Chinese PLA General Hospital (1) Mustafa Khasraw, MBChB, MD, FRCP, FRACP (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.